

THE LANCET

Global Health

Supplementary appendix 2

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Idro R, Ogwang R, Anguzu R, et al. Doxycycline for the treatment of nodding syndrome: a randomised, placebo-controlled, phase 2 trial. *Lancet Glob Health* 2024; published online May 13. [https://doi.org/10.1016/S2214-109X\(24\)00102-5](https://doi.org/10.1016/S2214-109X(24)00102-5).

Appendix 1
Supplementary files




Figure S1: Map showing study area in Northern Uganda




Figure S2: *Onchocerca volvulus* associated antibodies at baseline. Differences between treatment groups at baseline for antibodies A) anti Ov16, B) anti OvOC3261, C) anti Leiomodin-1 and D) anti DJ-1 IgG in plasma on Luciferase immunoprecipitation assays. Cerebrospinal fluid levels of E) anti Leiomodin-1 and F) anti DJ-1 IgG antibody concentrations at baseline on Luciferase immunoprecipitation assays. Blue dots represents individuals randomised to receive doxycycline while red dots show participants in the placebo group.

Table S1: Concentration of antibodies to *O.volvulus* antigens and to the HNPs measured by LIPS between baseline and 24 months

Outcome measures	Overall	Doxycycline	Placebo
<i>O.volvulus</i> Ov16 antibody concentration, signal to noise ratio			
Baseline, median (IQR)	25.62(8.74, 43.35)	22.75 (8.36, 39.69)	28.05 (9.23, 52.66)
After 24 months, median (IQR)	20.76(6.95, 50.27)	16.44 (6.36, 38.68)	27.93 (7.93, 65.96)
OvO3261 antibody concentration - signal to noise ratio			
Baseline, median (IQR)	7.32 (2.72, 9.51)	7.56 (3.27, 19.12)	7.25 (2.52, 20.1)
After 24 months, median (IQR)	2.67 (0.99, 7.15)	3.02 (1.06, 7.55)	2.06 (0.9, 6.85)
Antibody to human DJ-1 concentration in plasma on LPS, - signal to noise ratio			
Baseline, median (IQR)	1.47 (1.13, 2.79)	1.38 (1.14, 2.71)	1.57 (1.12, 3.05)
After 24 months, median (IQR)	1.26 (1.04, 1.75)	1.25 (1.04, 1.66)	1.27 (1.06, 1.81)
Human leiomodin-1 antibody concentration in plasma on LPS, signal to noise ratio			
Baseline, median (IQR)	1.38 (1.05, 2.29)	1.38 (0.98, 2.36)	1.45 (1.08, 2.25)
After 24 months, median (IQR)	1.66 (1.16, 2.76)	1.75 (1.15, 3.54)	1.64(1.16, 2.59)
Anti-human DJ-1 antibody concentration in CSF, signal to noise ratio			
Baseline, median (IQR)	1.07 (0.83, 1.42)	1.08 (0.83, 1.42)	1.06 (0.79, 1.41)
After 24 months, median (IQR)	1.16 (0.91, 2.2)	1.19 (0.95, 1.99)	1.07 (0.86, 2.84)
Human leiomodin-1 antibody concentration in CSF, signal to noise ratio			
Baseline, median (IQR)	0.91 (0.73, 1.17)	0.9 (0.71, 1.09)	0.93 (0.73, 1.24)
After 24 months, median (IQR)	1.22 (0.99, 1.41)	1.25 (1.04, 1.44)	1.17 (0.96, 1.37)

Table S2:
Seizure-related deaths in patients with nodding syndrome over 24 months.

	All, N=240	Doxycycline, N=120	Placebo, N=120
Seizure related deaths			
Burns	1 (7.7%)	0 (0%)	1 (11.1%)
Drowning	3 (23.1%)	1 (22.2%)	2 (25.0%)
Status Epilepticus or SUDEP	9 (69.2%)	3 (6%)	6 (%)
Total*	13 (100.0%)	4 (3.4%)	9 (7.50%)

**The death by road traffic accident was excluded. Only seizure related deaths are included.*